390 related articles for article (PubMed ID: 769970)
1. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
3. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
6. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
7. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
8. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Mitchell MS; Mokyr MB; Davis JM
J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Johnson RO; Metter G; Wilson W; Hill G; Krementz E
Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
[TBL] [Abstract][Full Text] [Related]
10. [DTIC in malignant melanoma: a perspective (author's transl)].
Kokoschka EM
Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
12. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
[TBL] [Abstract][Full Text] [Related]
14. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
16. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Carmo-Pereira J; Oliveira Costa F; Pimentel P
Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
[No Abstract] [Full Text] [Related]
17. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
18. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
[No Abstract] [Full Text] [Related]
20. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
